Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity
View Patent ↗The present invention relates to a dietary supplement and method for a rapidly dissolving and disintegrating solid oral dosage form. Specifically, the present invention provides dietary supplements and methods for the delivery of dietary supplements comprising Arginine or derivatives thereof and Xanthinol Nicotinate or derivatives thereof. By way of oral administration to an individual of said solid oral dosage form, a method of rapidly increasing nitric oxide activity in an individual is also provided.
1. A dietary supplement comprising L-Arginine, Xanthinol Nicotinate, and yohimbine.
2. The dietary supplement of claim 1 , further comprising Crospovidone or derivatives thereof.
3. The dietary supplement of claim, 1 further comprising Croscarmellose or derivatives thereof.
4. The dietary supplement of claim 1 , wherein from about 1% to about 10% of the L-Arginine is fine-milled.
5. The dietary supplement of claim 4 , wherein the L-Arginine that is fine-milled are between 2 nm and 50 nm in average particle size.
6. A method of decreasing the disintegration time of tablet comprising at least Arginine, Xanthinol Nicotinate and yohimbine as active ingredients, the method comprising adding a disintegrant to said composition.
7. The method of claim 6 wherein hydrophilic Croscarmellose or derivatives thereof are used as a tablet disintegrant.
8. The method of claim 7 wherein said hydrophilic Croscarmellose absorbs a liquid and swells resulting in the promotion of the dissolution and disintegration of a tablet.
9. The method of claim 7 wherein said Crocarmellose is embedded in and in communication with the constituents of a tablet wherein the exploitation the hydrophilic properties of Croscarmellose results in a rapid dissolution and disintegration of said tablet.
10. The method of claim 9 wherein the time to bioavailability of said active ingredients is decreased.
11. The method of claim 6 wherein hydrophilic Crospovidone or derivatives thereof are used as a tablet disintegrant.
12. The method of claim 11 wherein said hydrophilic Crospovidone absorbs liquids and swells resulting in the promotion of the dissolution and disintegration of a tablet.
13. The method of claim 11 wherein said Crospovidone is imbedded in and in communication with the constituents of a table wherein the exploitation the hydrophilic properties of Croscarmellose results in a rapid dissolution and disintegration of said tablet.
14. The method of claim 13 wherein the time to bioavailability of said active ingredients is decreased.
15. A method comprising the step of the administering to a human or an animal comprising a dietary supplement according to claim 1 .
16. A method comprising the step of the administering to a human or an animal comprising a dietary supplement according to claim 2 .
17. A method comprising the step of the administering to a human or an animal comprising a dietary supplement according to claim 3 .
18. A method comprising the step of the administering to a human or an animal comprising according a dietary supplement to claim 2 wherein said Croscarmellose decreases the dissolution and disintegration time when said dietary supplement is administered in the form of a tablet.
19. A method comprising the step of the administering to a human or an animal comprising according a dietary supplement to claim 3 wherein said Crospovidone decreases the dissolution and disintegration time when said dietary supplement is administered in the form of a tablet.
20. The dietary supplement according to any of claim 1 - 3 or 5 , wherein said dietary supplement is in a solid oral dosage form selected from the group consisting of tablets, capsules or caplets.
21. The dietary supplement according to claim 20 , wherein at least a portion of the L-Arginine is present within an immediate-release film coating.
22. The dietary supplement of claim 1 , further comprising Crospovidone or derivatives thereof, and Croscarmellose or derivatives thereof.
23. A dietary supplement comprising from about 1.0 g to about 6.0 g of L-Arginine, from about 0.050 g to about 1.50 g of Xanthinol Nicotinate, and about 0.0027 g of yohimbine HCl.
24. The dietary supplement of claim 23 , further comprising Crospovidone or derivatives thereof.
25. The dietary supplement of claim 23 , further comprising Croscarmellose or derivatives thereof.
26. The dietary supplement of claim 23 , further comprising Crospovidone or derivatives thereof, and Croscarmellose or derivatives thereof.
27. The composition of claim 23 , wherein from about 1% to about 10% of the L-Arginine is fine-milled.
28. The dietary supplement of claim 27 , wherein the L-Arginine that is fine-milled is between 2 nm and 50 nm in average particle size.
29. The dietary supplement according to any of claims 23 through 25 , wherein said dietary supplement is in a solid oral dosage form selected from the group consisting of tablets, capsules or caplets.
30. The dietary supplement according to claim 1 , wherein the dietary supplement comprises a solid oral dosage form.
31. The dietary supplement according to claim 27 , wherein the dietary supplement comprises a solid oral dosage form.
32. The dietary supplement according to claim 31 , wherein the solid oral dosage form is selected from the group consisting of tablets, capsules or caplets.
33. The dietary supplement according to claim 32 , wherein the tablets have a 100% dissolution time of about 15 minutes.
34. The dietary supplement according to claim 32 , wherein at least a portion of the L-Arginine is present within an immediate-release film coating.
35. The dietary supplement according to claim 23 , wherein the dietary supplement comprises a solid oral dosage form.
36. The dietary supplement according to claim 4 , wherein the dietary supplement comprises a solid oral dosage form.
37. The dietary supplement according to claim 36 , wherein the solid oral dosage form is selected from the group consisting of tablets, capsules or caplets.
38. The dietary supplement according to claim 37 , wherein the tablets have a 100% dissolution time of about 15 minutes.
39. The dietary supplement according to claim 37 , wherein at least a portion of the L-Arginine is present within an immediate-release film coating.